Organisation paid for research Program year 2025 Source: CMS Open Payments

Allegiance Research Specialists

Neither a doctor nor a teaching hospital

Research payments

$600,963

37 payments

Through program year 2025, Allegiance Research Specialists is reported as receiving $600,963 in research payments, across 37 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $393,478 2
2023 Research $404 1
2021 Research $20,363 3
2020 Research $9,335 5
2019 Research $177,383 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $375,978 1 payment
  2. Merck Sharp & Dohme Corporation $200,900 29 payments
  3. AstraZeneca Pharmaceuticals LP $17,500 1 payment
  4. Pfizer Inc. $4,300 4 payments
  5. AbbVie, Inc. $2,285 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight $375,978 1 payment
  2. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $105,664 11 payments
  3. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU $65,671 6 payments
  4. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $19,500 1 payment
  5. a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older $17,500 1 payment
  6. Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $4,550 2 payments
  7. A Phase 2A Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy Safety Tolerability and Pharmacokinetics of Pf06687234 As Addon Therapy to Infliximab in Active Ulcerative Colitis Subjects Who Are Not in Remission Build UC $3,896 3 payments
  8. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $2,335 5 payments
  9. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $2,318 2 payments
  10. M14-433 $2,285 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record